Rabbit Recombinant Monoclonal Cytokeratin 10 antibody - conjugated to HRP. Suitable for IHC-P, WB and reacts with Human samples.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
IHC-P | WB | |
---|---|---|
Human | Tested | Tested |
Mouse | Predicted | Predicted |
Rat | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 | Notes Perform heat-mediated antigen retrieval before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/5000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Plays a role in the establishment of the epidermal barrier on plantar skin (By similarity). Involved in the maintenance of cell layer development and keratin filament bundles in suprabasal cells of the epithelium (By similarity). (Microbial infection) Acts as a mediator of S.aureus adherence to desquamated nasal epithelial cells via clfB, and hence may play a role in nasal colonization. (Microbial infection) Binds S.pneumoniae PsrP, mediating adherence of the bacteria to lung cell lines. Reduction of levels of KRT10 keratin decrease adherence, overexpression increases adherence. Neither protein has to be glycosylated for the interaction to occur.
KPP, KRT10, Cytokeratin-10, Keratin-10, CK-10, K10
Rabbit Recombinant Monoclonal Cytokeratin 10 antibody - conjugated to HRP. Suitable for IHC-P, WB and reacts with Human samples.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Cytokeratin 10 also known as CK10 K10 or KRT10 is a type I keratin protein with a mass of about 59 kDa. Researchers recognize it as an important structural protein found mainly in the suprabasal layers of the epidermis where it contributes to maintaining the integrity and function of the skin barrier. Cytokeratin 10 is also expressed in other stratified squamous epithelia. Scientists use antibodies against cytokeratin 10 sometimes called 'lh2' and 'cytokeratin 10 anticuerpos' as neomarkers for identifying specific cell types in tissue studies.
Keratin proteins like cytokeratin 10 provide mechanical stability to cells and tissues. Cytokeratin 10 forms a heterodimer with keratin 1 (KRT1) creating a complex that plays a critical role in the cytoskeleton of keratinocytes. This structure supports cellular resilience against mechanical stresses helping maintain the integrity of epithelial tissues. Keratin 10 function is essential for normal skin development and differentiation highlighting its significance in epidermal morphogenesis.
Cytokeratin 10 is integral to the epidermal differentiation complex. This pathway involves many regulatory proteins and is essential for proper skin formation and repair. Cytokeratin 10 together with KRT1 contributes to the terminal differentiation of keratinocytes. Another key pathway is the cornification process where cytokeratin 10 helps form the protective outer layer of the skin. These biological roles place cytokeratin 10 at an essential point in maintaining skin homeostasis and function.
Abnormal expression or mutation of cytokeratin 10 leads to skin conditions like epidermolytic hyperkeratosis. This rare inherited disorder results in blistering and thickening of the skin. Cytokeratin 10 mutations often appear alongside changes in KRT1 due to their forming a functional pair indicating their collaborative role in disease manifestation. Additionally altered cytokeratin 10 expression can be associated with psoriasis as disrupted keratinocyte differentiation contributes to this inflammatory skin disease. Understanding these associations helps in studying and developing treatment strategies for skin disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
IHC image of Cytokeratin 10 staining in a section of formalin-fixed paraffin-embedded normal human skin*, performed on a Leica BOND. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab194232 at 1/100 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab194232 overnight at 4°C. Antibody binding was visualised using ECL development solution ECL Substrate Kit (High Sensitivity) ab133406.
All lanes: Western blot - HRP Anti-Cytokeratin 10 antibody [EP1607IHCY] (ab194232) at 1/5000 dilution
All lanes: HaCat whole cell lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 59 kDa
Observed band size: 60 kDa
Exposure time: 2min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com